Table 3.
Association of intravenous iron dose with time to all-cause, cardiovascular, and infection-related death
| Doses (mg) | n (patient-mo) | Percent | All-Cause Mortality | Cardiovascular Mortality | Infection-Related Mortalitya | |||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P Valueb | HR (95% CI) | P Valueb | HR (95% CI) | P Valueb | |||
| One-month iron exposure | ||||||||
| None | 90,178 | 34.32 | 0.98 (0.79 to 1.22) | 0.01 | 1.11 (0.84 to 1.48) | 0.66 | 0.92 (0.54 to 1.57) | 0.43 |
| >0–150 | 53,302 | 20.16 | Reference | Reference | Reference | |||
| >150–350 | 63,327 | 23.96 | 0.78 (0.64 to 0.95) | 1.08 (0.80 to 1.44) | 0.77 (0.47 to 1.26) | |||
| >350 | 56,993 | 21.56 | 0.79 (0.62 to 0.99) | 0.95 (0.70 to 1.29) | 1.26 (0.75 to 2.12) | |||
| Three-month iron exposure | ||||||||
| None | 45,247 | 19.17 | 1.19 (0.90 to 1.57) | 0.41 | 1.06 (0.72 to 1.54) | 0.49 | 0.86 (0.38 to 1.96) | 0.24 |
| >0–450 | 60,407 | 25.59 | Reference | Reference | Reference | |||
| >450–1050 | 81,396 | 34.48 | 0.99 (0.81 to 1.20) | 0.87 (0.67 to 1.14) | 0.99 (0.56 to 1.74) | |||
| >1050 | 49,038 | 20.77 | 1.09 (0.84 to 1.42) | 1.02 (0.74 to 1.41) | 1.69 (0.87 to 3.28) | |||
| Six-month iron exposure | ||||||||
| None | 18,555 | 9.19 | 1.24 (0.92 to 1.69) | 0.31 | 1.46 (0.98 to 2.16) | 0.28 | 0.75 (0.29 to 1.95) | 0.48 |
| >0–900 | 62,845 | 31.14 | Reference | Reference | Reference | |||
| >900–2100 | 95,058 | 47.10 | 0.98 (0.80 to 1.21) | 1.15 (0.85 to 1.56) | 0.98 (0.53 to 1.81) | |||
| >2100 | 25,375 | 12.57 | 1.12 (0.81 to 1.57) | 1.17 (0.76 to 1.79) | 1.59 (0.73 to 3.46) | |||
The weighting on cumulative iron doses received was on the basis of iron history, age, sex, race, ethnicity, baseline comorbidity at 90 days, baseline body mass index, cause of ESRD, year of starting dialysis, baseline iron doses, hemoglobinopathies, saturation of transferrin (TSat)/ferritin categories, hemoglobin categories, weekly erythropoietin (EPO) doses categories, change in EPO, interaction of TSat/ferritin categories and hemoglobin categories, albumin, creatinine, predialysis systolic BP, body weight, change in weight, vascular access type, noninfection-related hospitalization, and infection. Demographics and baseline comorbidity were included in the outcome models. HR, hazard ratio; 95% CI, 95% confidence interval.
Models were adjusted for all covariates included in all-cause and cardiovascular morality models, except recent infection.
Global tests of iron exposure.